title: Cyclophosphamide treatment of an SJL murine B-cell lymphoma increases the proportion of suppressive CD8+ over tumor-stimulatory CD4+ T-lymphocytes.
abstract: Lymphomas (formerly reticulum cell sarcomas (RCS)) which develop spontaneously in SJL mice are a murine counterpart of human low grade B-cell non-Hodgkin's lymphoma. Tumor cells stimulate proliferation of syngeneic CD4+ T-lymphocytes which secrete cytokines required for tumor growth. Cyclophosphamide treatment of tumor-bearing mice (RCS/Cy) decreases in vitro tumor-stimulated CD4+ T-cell proliferation and, in turn, tumor growth, in part, through the suppressive action of CD8+ T-lymphocytes. In RCS/Cy compared to untreated tumor-bearing (RCS5) mice we report marked in vivo decreases in: (1) the activation (CD44HI/CD45RBLO phenotype) and proliferation (S + G2M phases of the cell cycle) of CD4+ T-lymphocytes; (2) the ratio of activated and/or proliferating CD4+ to CD8+ T-lymphocytes, and; (3) the proliferation of tumor cells. Also, depletion of CD8+ T-lymphocytes from RCS/Cy mice abrogated much of the efficacy of the RCS/Cy treatment and led to changes in lymphoid populations more reminiscent of those in RCS5 than RCS/Cy mice. The data support our hypothesis that the RCS/Cy treatment achieves its efficacy by preventing the predominance of CD4+ over CD8+ T-lymphocytes which is essential to maximum tumor growth in RCS5 mice. The results imply that analogous B-cell lymphomas in humans also may be treatable by shifting the T-cell balance toward inhibitory CD8+ rather than the tumor-stimulatory CD4+ T-lymphocytes.
authors.affiliation: Wayne State University School of Medicine, Department of Immunology and Microbiology, Detroit, MI 48201-1998.
authors.forename: T
authors.initials: T
authors.lastname: Wrone-Smith
authors.forename: M
authors.initials: M
authors.lastname: Cankovic
authors.forename: E
authors.initials: E
authors.lastname: VanBuren
authors.forename: S
authors.initials: S
authors.lastname: Lerman
mesh_terms: D000818:Animals; D016516:CD4-CD8 Ratio; D002455:Cell Division; D003520:Cyclophosphamide / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005434:Flow Cytometry; D007958:Leukocyte Count; D008198:Lymph Nodes / Q000166:cytology; D008213:Lymphocyte Activation; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D013154:Spleen / Q000166:cytology
chemical_list: D003520:Cyclophosphamide